Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western Medicine
Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese Medicine and Western Medicine Based on Multi-omics
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Recruiting
- Jiaqi Chen
-
Contact:
- Jiaqi Chen, PhD
- Phone Number: +86-010-54205067
- Email: jiaqichen19@outlook.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Meets the 2002 AECG or 2016 ACR/EULAR classification criteria of primary Sjögren's syndrome.
Exclusion Criteria:
- Comorbid connective tissue disease other than the disease under research.
- Women who are pregnant or breastfeeding.
- Combined severe cardiovascular or cerebrovascular disease, hepatic or renal failure, or severe malignant tumors.
- Other conditions (e.g., cognitive impairment) that the investigators consider ineligible for enrollment.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Control group
|
|
Exposed group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with system involvement
Time Frame: Baseline , 6 months follow-up
|
System involvement determined from clinical diagnosis
|
Baseline , 6 months follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: Baseline , 6 months follow-up
|
All-cause mortality
|
Baseline , 6 months follow-up
|
|
Number of participants with tumor
Time Frame: Baseline , 6 months follow-up
|
Tumor determined from clinical diagnosis
|
Baseline , 6 months follow-up
|
|
Number of participants with connective tissue disease
Time Frame: Baseline , 6 months follow-up
|
Connective tissue disease determined from clinical diagnosis
|
Baseline , 6 months follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 2024-1-4065
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.